(A) A schematic representation of the secondary structure
organization of Eps8 actin binding domain. H1, H2, H3, H4,
and H5 indicate stretches of amino acids that adopt an helical
conformation; L1 is the 20 amino acid-long linker connecting H1 to H2
(see for additional details and amino acids sequence Figure S1B
and S1C). (B, C) H1–H2 and
H5 bind G-actin in a concentration-dependent manner. The
change in fluorescence of 1.5 µM NBD-labeled-actin was
measured at different concentrations of either H1–H2 (B) or H5
(C), in low salt (G buffer). Symbols indicate data; solid lines indicate
fitted binding curves for a complex with 1∶1 stoichiometry.
(D, E) H1–H2 and H5 inhibit barbed
and pointed end elongation rates with different thermodynamic
constants. The rate of elongation was measured from pointed
ends (circles), using gelsolin-actin seeds (5 nM) and 2 µM of
G-actin (10% pyrenyl-labeled), or from barbed ends
(triangles), using spectrin-actin seeds (2 nM), in the presence of
increasing concentrations of H1–H2 (D) or H5 (E), as
indicated. Rates are normalized taking as 100% the rate of
elongation measured in the absence of H1–H2 or H5. Kds are
reported in the text. (F) H5 sequesters G-actin but does not cap
filaments ends. The rate of elongation from barbed ends was
measured using actin seeds and 2 µM (closed triangles) or 4
µM (opened triangles) of G-actin (10%
pyrenyl-labeled) in the presence of increasing concentrations of H5. A
shift toward the left of the rate of elongation by H5 as the
concentration of G-actin used increased indicates that stoichiometric
concentrations of H5 with respect to actin are required for the
inhibition. (G) Summary of the equilibrium parameters for
binding of H1–H2 and H5 to monomeric actin. The
values were obtained as described in the methods from the experimental
curves show in (A–F). Please note that the Kd obtained from
the inhibition of pointed end growth experiments reflects the binding
affinity of the tested helices for monomeric actin leading to its
sequestration and were performed at physiological salt condition.